REBOOT #146 Pain Meds in CKD

<div>We tackle the complexities of pain management in patients with chronic kidney disease in this reboot from <a href="https://twitter.com/nephmadness">@NephMadness</a> 2019 that, on a scale of 1-10, will leave you feeling very relieved in addressing pain. Topics: Opioids, gabapentinoids, NSAIDS, pain ladders, why tramadol is tramadont, and more!</div> <div><br> </div> <div> <a href="https://thecurbsiders.com/episode-list">Episodes</a> | <a href="https://anchor.fm/s/4108bcf4/podcast/rss">Subscribe</a> | <a href="https://open.spotify.com/show/3SKlzOLxyztvA1BkJfnf67">Spotify</a> | <a href="https://www.teepublic.com/user/kashlakmemorial">Swag!</a> | <a href="https://thecurbsiders.com/top-picks">Top Picks</a> | <a href="https://thecurbsiders.com/knowledgefood">Mailing List</a> | <a href="mailto:thecurbsiders@gmail.com">thecurbsiders@gmail.com</a> | <a href="http://curbsiders.vcuhealth.org">Free CME!</a> </div> <div> <br> Credits</div> <ul> <li>Written and produced by: Justin Berk MD</li> <li>NephMadness Pain Region: Samantha Gelfand MD</li> <li>NephMadness Pun Contest produced by: Hannah R Abrams</li> <li>Cover art by: Kate Grant MBChB, Dip GUMed</li> <li>Hosts: Matthew Watto MD, Paul Williams MD, Stuart Brigham MD</li> <li>Edited by: Matthew Watto MD (audio), Emi Okamoto MD (show notes)</li> <li>Guests:  Samantha Gelfand MD, Matthew Sparks MD, David Juurlink MD</li> </ul> <div> <br> Show Segments</div> <ul> <li>Kidney Pun</li> <li>Disclaimer, intro and guest bios</li> <li>Guest one-liners</li> <li>Clinical Case and Pain Management Disclaimer</li> <li>Modalities for pain meds in ckd</li> <li>Opioids for pain and their metabolites</li> <li>Dave Juurlink reframes the question, “what is our real goal with pain management?”</li> <li>Matt Sparks reiterates the dangers of morphine and codeine in patients with advanced CKD</li> <li>Communicating meds that are contraindicated or relatively contraindicated in CKD</li> <li>Buprenorphine</li> <li>What about the WHO Pain Ladder for CKD?</li> <li>Should we use more cannabinoids?